Ignite Creation Date:
2025-12-24 @ 6:38 PM
Ignite Modification Date:
2026-01-03 @ 6:47 AM
Study NCT ID:
NCT03972657
Status:
RECRUITING
Last Update Posted:
2025-11-06
First Post:
2019-05-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Sponsor:
Regeneron Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-08-12
Start Date Type:
ACTUAL
Primary Completion Date:
2027-11-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-11-15
Completion Date Type:
ESTIMATED
First Submit Date:
2019-05-30
First Submit QC Date:
None
Study First Post Date:
2019-06-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-05
Last Update Post Date:
2025-11-06
Last Update Post Date Type:
ESTIMATED